TrimRX
US$ 24.60
pharma news today obesity drugs glp-1 health october 2025 Outlook for obesity in 2025: more ๐ The next trillion-dollar drug
Description
Practices that stay current on these developments and adapt their protocols accordingly will continue to deliver better outcomes
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): A double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Check out these articles:
He J, Wang C, Sun Y, et al
Rhodiola rosea root extract, standardized to 5% rosavins and 2% salidrosides
